Ifex
(ifosfamide)ApprovedSmall molecule
Ifosfamide is a chemotherapy drug used to treat various cancers including testicular cancer, lymphomas, and sarcomas. It works by damaging cancer cell DNA to prevent them from growing and dividing.[2] Ifex is currently approved and in use across 41 indications[4].[1]
Ifex is one of 448 small molecule programs targeting Pancreatic Neoplasm. It is currently in Approved.
41
Indications
309
Total Trials
15
Active Trials
447
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 40 indications
Competition
Competitive Landscape
370 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Ifex
BBaxter Healthcare Corporation
Approved
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma42 trials
Show 39 more trials
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Terminated·—·Phase 2·NCT00126191·10 enrolled
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Unknown status·—·Phase 1·NCT01884428·24 enrolled
Soft Tissue Sarcoma23 trials
Show 20 more trials
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003212·780 enrolled
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003052·340 enrolled
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Unknown status·EEuropean Paediatric Soft Tissue Sarcoma Study Group·Phase 3·NCT00334854·250 enrolled
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02808247·80 enrolled
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002641·350 enrolled
Germ Cell Tumor14 trials
Show 11 more trials
Osteosarcoma11 trials
Show 8 more trials
Acute Lymphoblastic Leukemia11 trials
Show 8 more trials
54 more indications
Leukemia7 trials
Show 4 more trials
Diffuse Large B-Cell Lymphoma7 trials
Show 4 more trials
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting·—·Phase 1/2·NCT02628405·30 enrolled
Neuroblastoma7 trials
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Completed·—·Phase 3·NCT00002802·500 enrolled
Show 4 more trials
Small Cell Lung Cancer5 trials
Rhabdomyosarcoma5 trials
Show 2 more trials
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
Unknown status·EEuropean Paediatric Soft Tissue Sarcoma Study Group·Phase 3·NCT00379457·600 enrolled
Radiation Therapy4 trials
Breast Cancer4 trials
Mantle Cell Lymphoma3 trials
Stem Cell Transplantation3 trials
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Completed·—·Phase 2·NCT00002601·13 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
Completed·—·Phase 2·NCT00002931·48 enrolled
Non-Small Cell Lung Cancer3 trials
Chemotherapy2 trials
Solid Tumors2 trials
Bone Marrow Transplantation2 trials
Ewing sarcoma2 trials
Anaplastic Large Cell Lymphoma2 trials
Lung Cancer2 trials
Primitive Neuroectodermal Tumor1 trial
Autologous Stem Cell Transplantation1 trial
Carboplatin1 trial
Fibrosarcoma1 trial
Efficacy and Safety1 trial
Peritoneal Cancer1 trial
Penile Cancer1 trial
Cervical Cancer1 trial
Advanced Sarcoma1 trial
Recurrent Cancer1 trial
Metastatic Solid Tumors1 trial
Recurrent or Refractory Solid Tumors1 trial
Hypofractionated Radiotherapy1 trial
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
Unknown status·—·Phase 2·NCT02812654·70 enrolled
Patients With Advanced Solid Tumors1 trial
Lymphoblastic Lymphoma1 trial
Stem Cell Transplant1 trial
Locally Advanced1 trial
Pancreatic Cancer1 trial
Glioma1 trial
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00278278·150 enrolled
Central Nervous System Germ Cell Tumor1 trial
Ewing's Sarcoma1 trial
Bladder Cancer1 trial
Testicular Cancer1 trial
Bone Sarcoma1 trial
Relapsed or Refractory1 trial
Neuroectodermal Tumors1 trial
Refractory Solid Tumors1 trial
Regulatory
FDA Approval Timeline[5]
Dec 30, 1988
IFEX
NDA NDA019763
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ifex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for ifosfamide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBaxter Healthcare Corporation